Association of common gene variants in the WNT/β-catenin pathway with colon cancer recurrence

1] Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA [2] Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
The Pharmacogenomics Journal (Impact Factor: 4.23). 07/2013; DOI: 10.1038/tpj.2013.20
Source: PubMed


Wnt/β-catenin signaling has a central role in the development and progression of most colon cancers (CCs). Germline variants in Wnt/β-catenin pathway genes may result in altered gene function and/or activity, thereby causing inter-individual differences in relation to tumor recurrence capacity and chemoresistance. We investigated germline polymorphisms in a comprehensive panel of Wnt/β-catenin pathway genes to predict time to tumor recurrence (TTR) in patients with stage III and high-risk stage II CC. A total of 234 patients treated with 5-fluorouracil-based chemotherapy were included in this study. Whole-blood samples were analyzed for putative functional germline polymorphisms in SFRP3, SFRP4, DKK2, DKK3, Axin2, APC, TCF7L2, WNT5B, CXXC4, NOTCH2 and GLI1 genes by PCR-based restriction fragment-length polymorphism or direct DNA sequencing. Polymorphisms with statistical significance were validated in an independent study cohort. The minor allele of WNT5B rs2010851 T>G was significantly associated with a shorter TTR (10.7 vs 4.9 years; hazard ratio: 2.48; 95% CI, 0.96-6.38; P=0.04) in high-risk stage II CC patients. This result remained significant in multivariate Cox's regression analysis. This study shows that the WNT5B germline variant rs2010851 was significantly identified as a stage-dependent prognostic marker for CC patients after 5-fluorouracil-based adjuvant therapy.The Pharmacogenomics Journal advance online publication, 2 July 2013; doi:10.1038/tpj.2013.20.

20 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Peroxiredoxin 2 (Prdx2) has been shown to act as an antioxidant whose main function is to reduce hydrogen peroxide (H2O2) in cells, and Prdx2 is abnormally elevated in colorectal cancer (CRC). However, the functional significance of this up-regulation and the detailed molecular mechanism behind the regulatory effect of Prdx2 on the growth of CRC cells have not been elucidated. In this study, we demonstrated that Prdx2 knockdown using a lentiviral vector-mediated specific shRNA inhibited cell growth, stimulated apoptosis, and augmented the production of endogenous reactive oxygen species (ROS). Further, silencing of Prdx2 resulted in an altered expression of proteins associated with the Wnt signaling pathway. Finally, Prdx2 knockdown contributed to attenuated CRC growth in BALB/c nude mice. In conclusion, these findings demonstrate that the regulatory effects of Prdx2 can be partially attributed to Wnt/β-catenin signaling.
    Cancer letters 10/2013; 343(2). DOI:10.1016/j.canlet.2013.10.002 · 5.62 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mucin 1 (Muc1) is a tumor-associated glycoprotein and has an important role in cancer progression and metastasis. The aim of the study was to explore the effects and mechanism of Muc1 silencing on proliferation and tumor-forming capacity of colon cancer cell lines. In the present study, we first screened the colon cancer cell lines with high expression of Muc1 by western blot analysis. Then, the effective siRNA was selected and used for silencing endogenous Muc1. The results by MTT and vitro scratch assay showed that interference of Muc1 could effectively inhibit HCC2998 proliferation and migration (p<0.01). Also, colony-forming ability in Muc1-siRNA groups was significantly decreased compared with the control group (p<0.01). Cell cycle is detected by flow cytometry that suggested that Muc1-siRNA1 induced cell cycle arrest at S phase in HCC2998. Next, the expression and distribution of β-catenin in cytoplasm and the nucleus was detected by western blot and the results revealed that the expression of β-catenin was redistributed in Muc1-siRNA group. A higher β-catenin level was detected in cytoplasm, while a lower β-catenin level was located in nucleus, compared with controls (p<0.05). The tumorigenicity experiments showed that inhibition of Muc1 could significantly suppress the growth of HCC2998 in nude mice models (p<0.01). This study would effectively provide new clues for colon cancer therapy.
    DNA and cell biology 01/2014; 33(3). DOI:10.1089/dna.2013.2274 · 2.06 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pericytes are crucial for angiogenesis. The impact of pericyte function to bevacizumab efficacy in mCRC treatment has not been comprehensively examined. This retrospective study investigated germline polymorphisms in genes related to early pericyte maturation to predict bevacizumab efficacy in 424 patients of two clinical trials treated first line with FOLFIRI+bevacizumab. Eight single-nucleotide polymorphisms (SNPs) were tested for potential biomarker value: RGS5 (regulator of G-protein signaling 5; rs1056515, rs2661280), PDGFR-β (platelet-derived growth factor receptor-β; rs2229562, rs2302273), CSPG4 (chondroitin sulfate proteoglycan NG2; rs8023621, rs1127648) and RALBP1 (RalA binding protein 1; rs10989, rs329007). For progression-free survival (PFS), PDGFR-β (rs2302273) was able to define significantly different patient cohorts in uni- and multivariate testing. RALPB1 (rs329007) showed predictive value for tumor response. The C allele in RGS5 (rs2661280) predicted longer overall survival and CSPG4 rs1127648 was associated with differences in PFS, but for both value was lost when multivariate analysis was applied. A comprehensive statistical analysis revealed that the biomarker value of the SNPs was dependent on primary tumor location. This is the first study to identify pericyte germline polymorphisms associated with clinical outcome in mCRC patients treated first line with FOLFIRI+bevacizumab. The differences seen with regard to primary tumor location may lead to further research to understand the clinical outcome differences seen in right- and left-sided colon cancer.The Pharmacogenomics Journal advance online publication, 29 July 2014; doi:10.1038/tpj.2014.40.
    The Pharmacogenomics Journal 07/2014; 15(1). DOI:10.1038/tpj.2014.40 · 4.23 Impact Factor
Show more